A Continuous Oral Regimen of High-Dose Cromolyn Sodium Is Effective for Some Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) Patients With Mast Cell Activation Syndrome. — CFSMEATLAS
A Continuous Oral Regimen of High-Dose Cromolyn Sodium Is Effective for Some Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) Patients With Mast Cell Activation Syndrome.
Christoforou, Maritsa E, van Campen, Linda C, Visser, Frans C et al. · Cureus · 2026 · DOI
Quick Summary
This study looked at five ME/CFS patients who also had mast cell activation syndrome (a condition where immune cells release too many chemicals). These patients took a medication called cromolyn sodium in higher doses than usual—up to 2400 mg per day instead of the standard 800 mg—by sipping it continuously throughout the day rather than taking four separate doses. All five patients reported improvements in their symptoms.
Why It Matters
Many ME/CFS patients experience mast cell activation as a complicating condition, and this report suggests that higher-dose cromolyn with continuous dosing may benefit a subset of these patients. The novel delivery method could improve medication compliance compared to standard four-times-daily regimens. This finding warrants further investigation through larger prospective trials.
Observed Findings
All five ME/CFS patients with mast cell activation syndrome showed clinical improvement with high-dose cromolyn (1600-2400 mg daily).
Standard-dose cromolyn (800 mg daily) was ineffective in these five patients after one week of treatment.
The continuous oral dosing regimen (dissolving daily dose in water and sipping throughout the day) was tolerated by all patients.
The high doses used remained within the safety parameters of the original FDA application for cromolyn.
Symptom control of mast cell activation signs and symptoms was achieved with the higher continuous regimen.
Inferred Conclusions
A continuous oral regimen of high-dose cromolyn (1600-2400 mg daily) may be effective for some ME/CFS patients with concurrent mast cell activation syndrome.
The continuous dosing method may offer theoretical advantages over conventional four-times-daily dosing, potentially improving compliance.
Some ME/CFS patients with MCAS may require doses substantially higher than the standard 800 mg daily to achieve symptom control.
Remaining Questions
Would this high-dose continuous regimen benefit ME/CFS patients with MCAS beyond this small sample, and what percentage of the ME/CFS population would respond?
What This Study Does Not Prove
This case series cannot establish that high-dose cromolyn is effective for all ME/CFS patients or even for most patients with MCAS—it describes only five cases. It does not prove causation or determine whether symptom improvement was due to cromolyn, the continuous dosing method, placebo effect, or natural disease fluctuation. Larger controlled trials are needed before recommending this approach as standard practice.
Tags
Method Flag:PEM Not DefinedWeak Case DefinitionNo ControlsSmall SampleExploratory Only